Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > REGULATORY
REGULATORY
- Decision on Long-Term Prescriptions to Be Based on Results of Discussions at CSIMC: Government
November 21, 2013
- Plan Floated to Merge NIBIO Unit, JST to Create Japan-Version NIH: Govt Source
November 20, 2013
- Finance Minister Pushes Drastic Price Cuts for Off-Patent Drugs with Low Generic Penetration
November 20, 2013
- Administrative Reform Council Calls for Further Promotion of Generics, Elimination of OTC-like Drugs from Insurance Coverage
November 20, 2013
- PAFSC’s Second Committee Supports Approval of NBI’s Lung Cancer Drug, Takeda’s Malignant Lymphoma Treatment
November 19, 2013
- PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29
November 19, 2013
- 1st Anticancer Drugs OK’ed for External Reviews under New Advanced Healthcare Scheme
November 18, 2013
- Subcommittee Agrees On Plan to Include Rate of Generic Drug Use in Determining Functional Evaluation Coefficient II for DPC Hospitals
November 18, 2013
- Reimbursement Listing of OBLEAN Put on Hold, Faces Rare CSIMC Setback
November 15, 2013
- MHLW Proposes Special Price Reductions for Long-Listed Drugs with Less than 60% of Generic Substitution After 5 Years
November 15, 2013
- Health Ministry Proposes to Set First Generic Prices at Half of Brand Name Drug Prices
November 14, 2013
- CSIMC OKs NHI Price Listing of 13 APIs, Takes Pass on Takeda’s OBLEAN
November 14, 2013
- Japan Govt OKs Bill to Allow Online Sales of OTC Drugs
November 14, 2013
- Expected Supplies for 4 Anti-Flu Drugs Announced for Flu Season; Tamiflu for 8 Million People
November 12, 2013
- 290 Billion Yen Invested for R&D by Drug Makers Receiving New Drug Development Premium: FPMAJ Survey
November 11, 2013
- Dr Nakagawa of JMA Says Japanese Drug Makers Should Prioritize Domestic Development
November 8, 2013
- CSIMC’s Expert Subcommittee to Present Concrete Plan on Cost-Effective Assessment by End of Year
November 8, 2013
- “Precursor Premium” Bashed by Healthcare Provider, Bill Payer Reps at CSIMC
November 7, 2013
- “Precursor Premium” Proposed at CSIMC Drug Pricing Subcommittee, Yet Further Deliberations Necessary
November 7, 2013
- Online Sales Banned for Three Years after Rx-to-OTC Switch
November 7, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…